Non-Small Cell Lung Cancer (NSCLC) Drug Pipeline Analysis Report 2024

Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer types. As per cancer.gov calculations, in 2024, around 234,580 new cases are likely to occur in the United States population. Moreover, 125,070 deaths are predicted in 2024. Hence, leading healthcare companies like AstraZeneca, Merck and Daiichi Sankyo along with research institutions are meticulously working to develop effective drugs for the treatment of the condition. This has led to a significant number of drugs currently in the development pipeline.

Key Takeaways

• Major companies involved in the non-small cell lung cancer (NSCLC) drugs market include AstraZeneca, Daiichi Sankyo Co., Ltd., GlaxoSmithKline, Bayer AG, Hoffmann-La Roche, Pfizer, Inc., and Merck KGaA, among others.

• Regulatory authorities like the United States FDA and EMA play a critical role in the drug pipeline as they provide fast-track approvals and breakthrough designations to expedite access to new and effective treatments.

• Leading drugs currently under the drug pipeline include Sasanlimab, HER3-DXd and Osimertinib, among others.

Report Coverage

The Non-Small Cell Lung Cancer (NSCLC) Drug Pipeline Report by Expert Market Research gives comprehensive insights on the non-small cell lung cancer (NSCLC) drugs currently undergoing clinical trials. It covers various aspects related to the details for each of these drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on non-small cell lung cancer (NSCLC).

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to non-small cell lung cancer (NSCLC) are covered.

Non-Small Cell Lung Cancer (NSCLC) Drug Pipeline Outlook

Non-small cell lung cancer (NSCLC) is the most commonly occurring lung cancer type and can be further categorized into squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. A variety of drugs are used to treat NSCLC, depending on the stage of the cancer, specific genetic mutations, and the overall health of the patient. These drugs can be categorized into several main classes such as chemotherapy, targeted therapy, and immunotherapy, among others. Chemotherapy includes platinum-based drugs, and antimetabolites while targeted therapy constitutes EGFR inhibitors, ALK inhibitors and ROS1 inhibitors. PD-1 and PD-L1 inhibitors are also common drug classes within immunotherapy drugs.

Common symptoms of non-small cell lung cancer (NSCLC) include persistent cough, chest pain, shortness of breath and fatigue. Smoking is one of the leading causes of the condition. Therefore, the increasing prevalence of smoking in the global population fuels the non-small cell lung cancer (NSCLC) market growth.

The non-small cell lung cancer (NSCLC) pipeline report covers the pathophysiology and epidemiology, developing treatment, and the progress and future aspects of ongoing clinical trials in detail.

Non-Small Cell Lung Cancer (NSCLC) Cancer – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of non-small cell lung cancer (NSCLC) drugs based on various segmentations such as:

By Phase

EMR’s pipeline assessment report covers 50+ drug analysis based on phase.

• Late-Stage Products (Phase 3 and Phase 4)

• Mid-Stage Products (Phase 2)

• Early-Stage Products (Phase I)

• Preclinical and Discovery Stage Products

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analysis based on the route of administration.

• Oral

• Parenteral

• Others

Non-Small Cell Lung Cancer (NSCLC) – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes in depth analysis of each drug across these phases. According to EMR analysis, phase II trials cover a major share of the total non-small cell lung cancer (NSCLC) clinical trials conducted, with approximately 3,000 plus drugs in the pipeline.

Non-Small Cell Lung Cancer (NSCLC)– Pipeline Assessment Segmentation, By Route of Administration

The route of administration categories covered under non-small cell lung cancer (NSCLC) pipeline analysis include oral, parenteral, and others. The report provides a comparative analysis of the route of administration for each drug in various phases of clinical trials. According to EMR analysis, the parenteral route holds a significant market share based on the route of administration.

Non-Small Cell Lung Cancer (NSCLC) Clinical Trials Assessment – Competitive Dynamics

The EMR report for non-small cell lung cancer (NSCLC) drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in pancreatic cancer clinical trials:

• AstraZeneca

• Daiichi Sankyo Co., Ltd.

• GlaxoSmithKline

• Bayer AG

• Hoffmann-La Roche

• Novartis Pharmaceuticals

• Seagen Inc.

• Pfizer, Inc.

• Merck KGaA

• Others

Non-Small Cell Lung Cancer (NSCLC) – Pipeline Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs. It covers include product description, trial ID, study type, drug class, mode of administration, and recruitment status of non-small cell lung cancer (NSCLC) clinical trial drugs.

Sasanlimab – Pfizer

Sasanlimab is a PD-1 antagonist monoclonal antibody, designed to be used in combination with a different targeted therapy in each set of the study. Sponsored by Pfizer, Sasanlimab is part of Landscape 1011 clinical research study for individuals with stage 3b or 4 NSCLC. Phase 1b of the sub-study will emphasize on the analyzing the safety while phase 2 will focus on evaluating anti-tumor activity in combination.

HER3-DXd – Daiichi Sankyo

Designed to treat metastatic or unresectable non-small cell lung cancer (NSCLC), Daiichi Sankyo’s HER3-DXd is being evaluated for its efficacy and antitumor activity. The Open-Label phase 1 study is divided into two parts, including dose expansion and dose escalation. It will be assessed on individuals with advanced NSCLC, having KRAS-G12C mutation.

Osimertinib – AstraZeneca

This interventional study by AstraZeneca evaluates neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus standard of care chemotherapy alone. Currently, under phase III, it is investigating the treatment in patients with resectable EGFRm non-small cell lung cancer.

Pembrolizumab (MK-3475) – Merck

As a part of KEYMAKER-U01 Substudy 1, a phase 2 umbrella study sponsored by Merck Sharp & Dohme LLC, pembrolizumab (MK-3475) PLUS chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, or MK-0482 is being evaluated for treating advanced non-small cell lung cancer.

Key Questions Answered in the Non-Small Cell Lung Cancer (NSCLC) – Pipeline Assessment Report

• What is the current landscape of non-small cell lung cancer (NSCLC) pipeline drugs?
• How many companies are developing non-small cell lung cancer (NSCLC) drugs?
• How many phase III and phase IV drugs are currently present in non-small cell lung cancer (NSCLC) pipeline drugs?
• Which companies/institutions are leading the non-small cell lung cancer (NSCLC) drug development?
• What is the efficacy and safety profiles of non-small cell lung cancer (NSCLC) pipeline drugs?
• What are the opportunities and challenges present in the non-small cell lung cancer (NSCLC) drug pipeline landscape?
• Which company is conducting major trials for non-small cell lung cancer (NSCLC) drugs?
• What are the geographies covered for clinical trials in non-small cell lung cancer (NSCLC)?
• What are emerging trends in non-small cell lung cancer clinical trials?

Related Reports

Lung Cancer Therapeutics Market

Cancer Screening Market

Cancer Therapeutics Market